Literature DB >> 12911539

Nephritogenic autoantibodies but absence of nephritis in Il-12p35-deficient mice with pristane-induced lupus.

Nicola Calvani1, Minoru Satoh, Byron P Croker, Westley H Reeves, Hanno B Richards.   

Abstract

BACKGROUND: There is strong evidence that Th1 cytokines are essential for disease in murine models of lupus. Interleukin-12 (IL-12) is essential for Th1 cell differentiation and induces interferon-gamma (IFN-gamma) production. Paradoxically, it has been suggested that an IL-12 defect drives the pathogenesis of lupus, although its precise role remains unclear. We investigated the role of IL-12 for lupus-like disease induced by pristane. IL-12p35-deficient (-/-) and control (+/+) BALB/c mice were treated with pristane or phosphate-buffered saline (PBS).
METHODS: Proteinuria was measured and renal pathology evaluated 10 months after treatment. Sera were analyzed for autoantibodies and total immunoglobulin levels. Cytokine expression and production was analyzed.
RESULTS: Pristane induced nephritogenic autoantibodies and renal immunoglobulin and complement deposition in both IL-12 -/- and +/+ mice. However, proliferative pathology and proteinuria were absent in IL-12-/- mice, whereas pristane induced severe nephritis in one third of the +/+ mice. As expected, cytokine balance was skewed toward a Th2 response in pristane-treated IL-12 -/- mice.
CONCLUSION: These data indicate that renal immune complex deposition can occur in the absence of IL-12p35, but that structural renal damage requires the presence of IL-12p35 or mediators induced by this molecule, such as IFN-gamma. In contrast to the abrogation of nephritogenic autoantibodies by the lack of IFN-gamma, such antibodies are induced by pristane in IL-12p35-deficient mice. Absence of structural renal disease, despite the presence of nephritogenic autoantibodies in pristane-treated IL-12-/- mice, indicates that antibody deposition alone is not sufficient for the development of lupus nephritis in this model.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12911539     DOI: 10.1046/j.1523-1755.2003.00178.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  22 in total

1.  Modulation of the immune response in pristane-induced lupus by expression of activation and inhibitory Fc receptors.

Authors:  Raphael Clynes; Nicola Calvani; Byron P Croker; Hanno B Richards
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

2.  IL-12 Blocks Tfh Cell Differentiation during Salmonella Infection, thereby Contributing to Germinal Center Suppression.

Authors:  Rebecca A Elsner; Mark J Shlomchik
Journal:  Cell Rep       Date:  2019-11-26       Impact factor: 9.423

3.  Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane).

Authors:  Dina C Nacionales; Kindra M Kelly; Pui Y Lee; Haoyang Zhuang; Yi Li; Jason S Weinstein; Eric Sobel; Yoshiki Kuroda; Jun Akaogi; Minoru Satoh; Westley H Reeves
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

4.  Interleukin-17A promotes early but attenuates established disease in crescentic glomerulonephritis in mice.

Authors:  Dragana Odobasic; Poh-Yi Gan; Shaun A Summers; Tim J Semple; Ruth C M Muljadi; Yoichiro Iwakura; A Richard Kitching; Stephen R Holdsworth
Journal:  Am J Pathol       Date:  2011-07-08       Impact factor: 4.307

5.  The natural killer T cell ligand alpha-galactosylceramide prevents or promotes pristane-induced lupus in mice.

Authors:  Avneesh K Singh; Jun-Qi Yang; Vrajesh V Parekh; Jie Wei; Chyung-Ru Wang; Sebastian Joyce; Ram R Singh; Luc Van Kaer
Journal:  Eur J Immunol       Date:  2005-04       Impact factor: 5.532

6.  Experimental lupus is aggravated in mouse strains with impaired induction of neutrophil extracellular traps.

Authors:  Deborah Kienhöfer; Jonas Hahn; Julia Stoof; Janka Zsófia Csepregi; Christiane Reinwald; Vilma Urbonaviciute; Caroline Johnsson; Christian Maueröder; Malgorzata J Podolska; Mona H Biermann; Moritz Leppkes; Thomas Harrer; Malin Hultqvist; Peter Olofsson; Luis E Munoz; Attila Mocsai; Martin Herrmann; Georg Schett; Rikard Holmdahl; Markus H Hoffmann
Journal:  JCI Insight       Date:  2017-05-18

7.  Endogenous interleukin (IL)-17A promotes pristane-induced systemic autoimmunity and lupus nephritis induced by pristane.

Authors:  S A Summers; D Odobasic; M B Khouri; O M Steinmetz; Y Yang; S R Holdsworth; A R Kitching
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

8.  TACI deletion protects against progressive murine lupus nephritis induced by BAFF overexpression.

Authors:  Tanvi Arkatkar; Holly M Jacobs; Samuel W Du; Quan-Zhen Li; Kelly L Hudkins; Charles E Alpers; David J Rawlings; Shaun W Jackson
Journal:  Kidney Int       Date:  2018-06-12       Impact factor: 10.612

9.  A novel type I IFN-producing cell subset in murine lupus.

Authors:  Pui Y Lee; Jason S Weinstein; Dina C Nacionales; Philip O Scumpia; Yi Li; Edward Butfiloski; Nico van Rooijen; Lyle Moldawer; Minoru Satoh; Westley H Reeves
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

Review 10.  Induction of autoimmunity by pristane and other naturally occurring hydrocarbons.

Authors:  Westley H Reeves; Pui Y Lee; Jason S Weinstein; Minoru Satoh; Li Lu
Journal:  Trends Immunol       Date:  2009-08-19       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.